Austin, Texas, June 18th, 2026, FinanceWire
Earth Science Tech (OTC: ETST) reported financial results for the fiscal year ended March 31, 2026, highlighted by revenue of $35.7 million, up 8% from the prior year, gross profit of $25.5 million, up 5%, and net income of $3.6 million, an 11% increase compared with fiscal 2025. Total assets rose 27% year over year to $9.0 million as the company continued expanding its integrated healthcare platform across telemedicine, pharmacy and fulfillment services.
The company also emphasized its capital allocation strategy, noting it repurchased and retired more than 4 million shares during fiscal 2026 and more than 7.1 million shares through fiscal 2026 and subsequent periods. Management said the company generated positive operating cash flow, strengthened its balance sheet without adding debt and remains focused on growth initiatives, product expansion and continued share repurchases as it enters fiscal 2027.
To view the full press release, visit https://ibn.fm/NpjTw
About Earth Science Tech, Inc.
Earth Science Tech, Inc. operates as a diversified holding company focused on the health and wellness sector. The Company’s principal operating strategy is to build a vertically integrated healthcare platform that combines compounding pharmacy operations, telemedicine platforms, clinical support, and direct-to-patient fulfillment. The Company’s healthcare operations are supported by investments in real estate and asset management activities and a consumer products business.
The core of the Company’s value proposition is the seamless integration of patient care, from consultation to fulfillment. This is achieved through the synergy of specialized subsidiaries.
NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at https://ibn.fm/ETST
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN